Side-by-side · Research reference
ARA 290vsDermorphin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED17/59 cited
BAnimal-StrongHUMAN-REVIEWED20/47 cited
Dermorphin
Opioid Peptide · μ-Receptor Agonist · Research Only
Research only · ICV / SC (animal models)
01Mechanism of Action
Parameter
ARA 290
Dermorphin
Primary target
Innate repair receptor (EPO receptor / CD131 heterodimer)
μ-opioid receptors (central and peripheral)Negri 1992Steel 2014
Pathway
EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades
μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization
Downstream effect
Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014Culver 2017
Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects
Feedback intact?
N/A — does not interact with hematopoietic EPO receptorLiu 2014
N/A — exogenous opioid agonist
Origin
11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties
Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998Mignogna 1992
Antibody development
Not reported in clinical trials
Site-directed antibodies produced for detection and purificationCucumel 1996
02Dosage Protocols
Parameter
ARA 290
Dermorphin
Standard dose (Phase 2)
4 mg / dayBrines 2015Culver 2017
Sarcoidosis SFN and diabetic neuropathy trials.
—
Frequency
Once daily
Self-administered subcutaneously.
—
Evidence basis
Phase 2 RCTsCulver 2017Brines 2015
64-subject sarcoidosis trial, type 2 diabetes trial.
Animal studies · In vitro assays
Timing
Any time of day
No circadian dependence reported.
—
Legal status
—
Controlled substance in many jurisdictions · Research only
Not approved for human use.
Animal research (ICV)
—
Low nanomolar to picomolar range
Intracerebroventricular administration in rodent models.
Detection limit (doping)
—
5 pg/mL in equine plasma/urineSteel 2014
High-throughput LC-MS/MS screen developed for racing industry.
Duration of action
—
10–120 minutes (dose-dependent, intrathecal)
Human toxicity
—
Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025
03Metabolic / Fat Loss Evidence
Parameter
ARA 290
Dermorphin
Primary effect
Improved metabolic control (HbA1c, fasting glucose)Brines 2015
Secondary to neuropathy treatment; direct lipolytic effects not established.
—
HbA1c
Significant reduction vs placebo
Observed in type 2 diabetes + neuropathy trial.
—
Fasting glucose
Improved in ARA 290 group
—
Body composition
Not directly quantified
Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.
—
04Side Effects & Safety
Parameter
ARA 290
Dermorphin
Injection site reaction
Mild, transient
—
Hematopoiesis
None — non-erythropoietic
Distinguishes ARA 290 from native EPO.
—
Cardiovascular
No thrombotic events or hypertension reported
—
Immunogenicity
No antibody formation reported
—
Opioid effects
—
Respiratory depression, sedation, euphoria, tolerance, dependence risk
Kambô ritual toxicity
—
Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025
Receptor selectivity caveat
—
Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992
Proteolytic stability
—
Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996
Absolute Contraindications
ARA 290
- ·Hypersensitivity to ARA 290
Dermorphin
- ·Human use — not approved by any regulatory authority
- ·Controlled substance status — possession illegal in many jurisdictions
- ·Known opioid hypersensitivity or respiratory compromise
Relative Contraindications
ARA 290
- ·Active malignancy (theoretical EPO-axis concern; not observed in trials)
Dermorphin
- ·Any context outside approved animal research protocols
- ·CNS depressant co-administration
05Administration Protocol
Parameter
ARA 290
Dermorphin
1. Preparation
Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.
Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.
2. Injection site
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.
In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.
3. Timing
Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015
High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014
4. Dosing
4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017
Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025
5. Storage
Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.
—
06Stack Synergy
ARA 290
+ BPC-157
ModerateARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.
- ARA 290
- 4 mg SQ · daily
- BPC-157
- 250–500 mcg SQ · daily
- Frequency
- Once daily, same or separate injections
- Primary benefit
- Nerve regeneration, pain reduction, tissue healing
Dermorphin
— no documented stacks